The Guardian documents brands scrapping plus sizes in the GLP-1 era

Fashion brands are quietly deleting their biggest sizes, and retail analysts say weight-loss drugs are a major reason why. A Guardian investigation published August 20, 2026, used data from the retail tracking firm Edited to show that several mainstream retailers cut plus-size inventory this spring and summer, while some shifted from numeric sizes to alpha sizing to better handle customers whose bodies are changing ^[1].

The sharpest example is H&M. Edited tracked every new women's dress landing on the retailer's site from January to May and compared 2026 with the same period in 2025. In 2025, sizes 3XL and 4XL made up 2% of new inventory. In 2026, those sizes were gone entirely. XXL, which had been 13.3% of inventory, fell by 3 percentage points; XL fell by 2 points; and sizes XS through large rose by an average of 3 points ^[1]. H&M told the Guardian it monitors fit and sizing demand and "we have chosen to discontinue sizes 3XL and 4XL, as we have seen lower demand for these sizes" ^[1].

Other brands moved the same direction. Mango cut new dresses in sizes 16 to 20 from 6.6% of inventory in spring/summer 2025 to 0.5% in 2026, and Anthropologie's July 2026 dress assortment dropped from 10.5% plus-size to 9% year over year ^[1]. That follows earlier retreats: Loft closed its plus range in 2021, Old Navy scaled back in May 2022, and last year the plus-size chain Torrid closed 151 locations — nearly a third of its stores ^[1].

The numbers behind the shift

Mintel research cited by the Guardian found 18% of US adults reported using GLP-1 drugs as of June 2025, up from 12% in 2024 ^[1]. Gallup data show the US adult obesity rate appeared to peak at 39.9% in 2022 and has fallen to 36.4% this year ^[1]. Impact Analytics CEO Prashant Agrawal called GLP-1s the "number one reason" apparel retailers are anxious about sizing right now ^[1].

But the actual sales shifts his firm measured are small. Extra-small garment sales rose 0.45% between 2023 and 2024 and 0.43% between 2024 and 2025, while sizes XL and larger fell 0.38% and 0.39% over the same periods, with medium and large down by even less ^[1]. For brands ordering billions of units in advance, small percentages matter financially — but they do not describe a country that has stopped needing large clothes. Most GLP-1 users lose between 10% and 20% of their body weight, and Plunkett Research estimated last year that 66% of US women still wear size 14 or above ^[1].

One notable change is how clothes are labeled. Edited's Krista Corrigan said Anthropologie is switching many garments from numeric to alpha sizes — medium instead of 14 — because letter sizes "absorb minor body fluctuations better than tailored numeric fits" for "consumers undergoing body transitions" ^[1]. Walmart, by contrast, added inventory for larger customers this season ^[1].

The visual side of fashion has shifted too. Data from the fall/winter 2026/2027 fashion weeks showed only 0.3% of runway models were plus-size, a historic low ^[2].

Why it matters for patients

People taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) often move through several sizes over a year or more. Shrinking size ranges can make that transition harder and more expensive for anyone whose body is between the sizes a store carries — including people who lose weight but still wear plus sizes.

Resale is absorbing some of that demand. ThredUp reported listings of larger garments up 32% year over year in the first half of 2026, roughly double the level of early 2023, while purchase volume for large, XL and plus-size women's apparel grew 17.4% this year versus 6.8% for small and medium ^[1]. The company says it has no data linking that to GLP-1 use ^[1].

There is also a cost-and-access angle. A Danish study of 4.5 million adults found the share of people redeeming a semaglutide prescription rose with income, even though obesity was more common at lower incomes ^[1]. Mintel's Brittany Steiger argued the core issue is fit, not shrinking bodies, noting 69% of shoppers say brands need more size and length options ^[1].

Clinicians quoted by Elle Canada also flagged medical context that marketing often skips: common GLP-1 side effects include nausea, vomiting, diarrhea, constipation and abdominal pain, and the drugs can involve loss of bone and muscle mass and nutritional deficiencies ^[2].

Whether these size cuts stick is not yet known. The Edited figures cover single seasons at a handful of retailers, not the whole market ^[1].